Sun Pharmaceutical Industries Ltd.
SUNPHARMAHealthcare filings
Earnings calls
23 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 23 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210602 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210806 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211111 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220203 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220602 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220803 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221105 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230201 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230531 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230809 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231108 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240206 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240529 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240807 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241104 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250206 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250529 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250806 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251111 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260204 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260505 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260529 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260806 | 2026-06-30 | yes |
Model workbook
Download SUNPHARMA_model_v2.xlsx — every figure in it names the filing, the reporting context and the period it was read from.
Commentary — cross-call tabulation
| Quarter | Theme | Management sentences | Analyst sentences | Management share |
|---|---|---|---|---|
| Q1FY22 | AI and technology | 1 | 0 | 0.01 |
| Q1FY22 | Capex and capacity | 0 | 0 | 0.00 |
| Q1FY22 | Capital allocation | 0 | 0 | 0.00 |
| Q1FY22 | Competition | 4 | 4 | 0.02 |
| Q1FY22 | Credit quality | 0 | 0 | 0.00 |
| Q1FY22 | Currency and macro | 2 | 0 | 0.01 |
| Q1FY22 | Demand and volumes | 1 | 1 | 0.01 |
| Q1FY22 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q1FY22 | Distribution and persistency | 3 | 2 | 0.02 |
| Q1FY22 | Margins and costs | 6 | 4 | 0.03 |
| Q1FY22 | People and attrition | 0 | 0 | 0.00 |
| Q1FY22 | Pricing and realisation | 13 | 5 | 0.07 |
| Q1FY22 | Raw materials and input costs | 0 | 0 | 0.00 |
| Q1FY22 | Regulation and policy | 1 | 0 | 0.01 |
| Q1FY23 | AI and technology | 0 | 0 | 0.00 |
| Q1FY23 | Capex and capacity | 3 | 4 | 0.01 |
| Q1FY23 | Capital allocation | 3 | 0 | 0.01 |
| Q1FY23 | Competition | 3 | 1 | 0.01 |
| Q1FY23 | Credit quality | 0 | 1 | 0.00 |
| Q1FY23 | Currency and macro | 3 | 1 | 0.01 |
| Q1FY23 | Demand and volumes | 4 | 12 | 0.02 |
| Q1FY23 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q1FY23 | Distribution and persistency | 0 | 0 | 0.00 |
| Q1FY23 | Margins and costs | 2 | 8 | 0.01 |
| Q1FY23 | People and attrition | 0 | 0 | 0.00 |
| Q1FY23 | Pricing and realisation | 6 | 6 | 0.03 |
| Q1FY23 | Raw materials and input costs | 0 | 0 | 0.00 |
| Q1FY23 | Regulation and policy | 2 | 0 | 0.01 |
| Q1FY24 | AI and technology | 0 | 0 | 0.00 |
| Q1FY24 | Capex and capacity | 1 | 2 | 0.00 |
| Q1FY24 | Capital allocation | 0 | 1 | 0.00 |
| Q1FY24 | Competition | 4 | 1 | 0.02 |
| Q1FY24 | Credit quality | 2 | 1 | 0.01 |
| Q1FY24 | Currency and macro | 3 | 3 | 0.01 |
| Q1FY24 | Demand and volumes | 3 | 3 | 0.01 |
| Q1FY24 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q1FY24 | Distribution and persistency | 4 | 2 | 0.02 |
| Q1FY24 | Margins and costs | 3 | 1 | 0.01 |
| Q1FY24 | People and attrition | 0 | 0 | 0.00 |
| Q1FY24 | Pricing and realisation | 6 | 3 | 0.03 |
| Q1FY24 | Raw materials and input costs | 0 | 0 | 0.00 |
| Q1FY24 | Regulation and policy | 1 | 1 | 0.00 |
| Q1FY25 | AI and technology | 0 | 0 | 0.00 |
| Q1FY25 | Capex and capacity | 3 | 2 | 0.02 |
| Q1FY25 | Capital allocation | 0 | 0 | 0.00 |
| Q1FY25 | Competition | 3 | 1 | 0.02 |
| Q1FY25 | Credit quality | 0 | 3 | 0.00 |
| Q1FY25 | Currency and macro | 2 | 0 | 0.01 |
| Q1FY25 | Demand and volumes | 6 | 7 | 0.04 |
| Q1FY25 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q1FY25 | Distribution and persistency | 2 | 1 | 0.01 |
| Q1FY25 | Margins and costs | 4 | 7 | 0.03 |
| Q1FY25 | People and attrition | 0 | 0 | 0.00 |
| Q1FY25 | Pricing and realisation | 5 | 2 | 0.03 |
| Q1FY25 | Raw materials and input costs | 0 | 0 | 0.00 |
| Q1FY25 | Regulation and policy | 1 | 0 | 0.01 |
| Q1FY26 | AI and technology | 0 | 0 | 0.00 |
| Q1FY26 | Capex and capacity | 1 | 3 | 0.00 |
| Q1FY26 | Capital allocation | 1 | 0 | 0.00 |
| Q1FY26 | Competition | 2 | 1 | 0.01 |
| Q1FY26 | Credit quality | 1 | 0 | 0.00 |
| Q1FY26 | Currency and macro | 2 | 0 | 0.01 |
| Q1FY26 | Demand and volumes | 3 | 3 | 0.01 |
| Q1FY26 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q1FY26 | Distribution and persistency | 3 | 1 | 0.01 |
| Q1FY26 | Margins and costs | 6 | 7 | 0.03 |
| Q1FY26 | People and attrition | 0 | 0 | 0.00 |
| Q1FY26 | Pricing and realisation | 4 | 1 | 0.02 |
| Q1FY26 | Raw materials and input costs | 1 | 0 | 0.00 |
| Q1FY26 | Regulation and policy | 3 | 6 | 0.01 |
| Q1FY27 | AI and technology | 0 | 0 | 0.00 |
| Q1FY27 | Capex and capacity | 2 | 1 | 0.01 |
| Q1FY27 | Capital allocation | 4 | 0 | 0.02 |
| Q1FY27 | Competition | 1 | 0 | 0.00 |
| Q1FY27 | Credit quality | 0 | 0 | 0.00 |
| Q1FY27 | Currency and macro | 3 | 0 | 0.01 |
| Q1FY27 | Demand and volumes | 10 | 4 | 0.04 |
| Q1FY27 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q1FY27 | Distribution and persistency | 0 | 0 | 0.00 |
| Q1FY27 | Margins and costs | 5 | 6 | 0.02 |
| Q1FY27 | People and attrition | 0 | 1 | 0.00 |
| Q1FY27 | Pricing and realisation | 3 | 4 | 0.01 |
| Q1FY27 | Raw materials and input costs | 0 | 0 | 0.00 |
| Q1FY27 | Regulation and policy | 1 | 0 | 0.00 |
| Q2FY22 | AI and technology | 0 | 0 | 0.00 |
| Q2FY22 | Capex and capacity | 4 | 2 | 0.02 |
| Q2FY22 | Capital allocation | 2 | 4 | 0.01 |
| Q2FY22 | Competition | 3 | 1 | 0.01 |
| Q2FY22 | Credit quality | 0 | 0 | 0.00 |
| Q2FY22 | Currency and macro | 2 | 0 | 0.01 |
| Q2FY22 | Demand and volumes | 4 | 1 | 0.02 |
| Q2FY22 | Deposits and liquidity | 0 | 0 | 0.00 |
| Q2FY22 | Distribution and persistency | 2 | 0 | 0.01 |
| Q2FY22 | Margins and costs | 10 | 8 | 0.05 |
| Q2FY22 | People and attrition | 0 | 0 | 0.00 |
| Q2FY22 | Pricing and realisation | 3 | 2 | 0.01 |
| Q2FY22 | Raw materials and input costs | 1 | 2 | 0.00 |
| Q2FY22 | Regulation and policy | 1 | 0 | 0.00 |
| Q2FY23 | AI and technology | 0 | 0 | 0.00 |
| Q2FY23 | Capex and capacity | 3 | 2 | 0.01 |
| Q2FY23 | Capital allocation | 0 | 2 | 0.00 |
| Q2FY23 | Competition | 3 | 0 | 0.01 |
| Q2FY23 | Credit quality | 0 | 1 | 0.00 |
| Q2FY23 | Currency and macro | 3 | 0 | 0.01 |
| Q2FY23 | Demand and volumes | 0 | 1 | 0.00 |
| Q2FY23 | Deposits and liquidity | 1 | 0 | 0.00 |
| Q2FY23 | Distribution and persistency | 1 | 0 | 0.00 |
| Q2FY23 | Margins and costs | 4 | 6 | 0.02 |
| Q2FY23 | People and attrition | 0 | 0 | 0.00 |
| Q2FY23 | Pricing and realisation | 1 | 4 | 0.00 |
| Q2FY23 | Raw materials and input costs | 0 | 0 | 0.00 |
| Q2FY23 | Regulation and policy | 1 | 0 | 0.00 |
| Q2FY24 | AI and technology | 0 | 0 | 0.00 |
| Q2FY24 | Capex and capacity | 1 | 5 | 0.01 |
| Q2FY24 | Capital allocation | 0 | 4 | 0.00 |
| Q2FY24 | Competition | 4 | 0 | 0.03 |
| Q2FY24 | Credit quality | 0 | 1 | 0.00 |
| Q2FY24 | Currency and macro | 2 | 0 | 0.01 |
| Q2FY24 | Demand and volumes | 2 | 2 | 0.01 |
| Q2FY24 | Deposits and liquidity | 0 | 0 | 0.00 |
Guidance items
| quarter | metric | direction | sentence | page |
|---|---|---|---|---|
| Q4FY21 | other | nan | For the full year FY21, the specialty business has grown over previous year despite the sharp reduction of sales in Q1 on account of the global pandemic. | 8 |
| Q4FY21 | other | nan | For the full year, R&D investments was Rs. 21,499 million accounting for about 6.5% of sales. | 9 |
| Q4FY21 | other | nan | And lastly on the guidance for FY22. | 9 |
| Q4FY21 | other | nan | Given the uncertainties of the pandemic in the near term, we are refraining from giving a guidance for FY22. | 9 |
| Q4FY21 | other | nan | One is, total R&D expenses will go up and within that the percentage of the money spent on innovative R&D also is likely to go up. | 12 |
| Q4FY21 | other | nan | Since we’re not giving any specific guidance, but generally we’ve tried to keep our | 12 |
| Q4FY21 | other | nan | So, general guidance is that what you see as a significant reduction in the marketing spend in all markets is likely to go up. | 13 |
| Q4FY21 | other | nan | We don’t have clarity because this was launched only towards the end of April…. even May has not closed for me, so, difficult to assess impact, fingers crossed | 13 |
| Q4FY21 | other | nan | However, having said that, we also launched our own authorized generic and we have locked up a few customers whom we have targeted for our share of the market. | 13 |
| Q4FY21 | other | nan | And hopefully this time we should be able to clear it successfully, that’s the focus. | 14 |
| Q4FY21 | other | nan | So, we will get some short-term benefit in next financial year. | 17 |
| Q1FY22 | other | nan | It is already approved by the USFDA and we expect to commercialize it in the US in the Oct-Dec 2021 quarter. | 7 |
| Q1FY22 | other | nan | Our expectation is that WINLEVI could have far more broad-based appeal, so for us to be able to handle two acne products in the same thing like you thought it w | 9 |
| Q1FY22 | volume | nan | So, Japan, I think we are in the process of getting entry into hospitals because unlike many other countries, Japan still has restrictions on COVID and medical | 11 |
| Q1FY22 | other | nan | He is asking AG, authorized generic, I think it will be in the generic sales. | 12 |
| Q1FY22 | other | nan | No, we shared a period that hopefully by next year or in subsequent year, it will become positive. | 13 |
| Q1FY22 | other | nan | I mean if we are able to gain market share and grow, then hopefully we should be able to and I think that I am happy with the progress that we are making. | 13 |
| Q1FY22 | pricing | nan | So at any point of time, there are products which are, let us say, likely to see a price increase, at the same point of time, there are products which are likel | 17 |
| Q1FY22 | other | nan | Because current COVID status across different markets is very different and we have no understanding of how that is likely to impact the business and I am talki | 18 |
| Q1FY22 | other | nan | Let us say, even in India, we are looking at a potential third wave and we have no understanding of how severe that wave will be, so in such a situation to give | 18 |
| Q1FY22 | other | nan | So, when we say normalized, I mean it is up from the COVID times, but I don’t think it is back to where it should be in a pre- COVID environment. | 20 |
| Q1FY22 | other | nan | So, two ways of looking at the whole thing and your second question was share of ILUMYA, the IL-23 market, I think don’t recall the exact number, but in the bal | 20 |
| Q2FY22 | other | nan | I don’t think we ever said that there’ll be a break even across the board next year. | 12 |
| Q2FY22 | other | nan | No, no real guidance really, we don’t give those details, business-by-business of course. | 12 |
| Q2FY22 | other | nan | We have indicated that the product that we have chosen is a product which is likely to be in the third wave of biosimilars, which means that potential patent ex | 20 |
| Q2FY22 | other | nan | No I really cannot give any guidance on that. | 20 |
| Q2FY22 | other | nan | We have to find creative ways of getting back to where we should be and keep moving forward. | 22 |
| Q2FY22 | other | nan | So, we stand with the same guidance as we progress. | 24 |
| Q3FY22 | other | nan | And I think the visibility I have as of now, going ahead, is also we don't look at it as each quarter, but average for each quarter should be in the same range | 13 |
| Q3FY22 | other | nan | So, rather than answer it as a next quarter question, I would look at enough headroom for the businesses to grow their own franchises. | 13 |
| Q3FY22 | other | nan | I think our sense is that the steady state R&D should be around 8%-9%. | 16 |
| Q3FY22 | other | nan | And I think depending on how the clinical trial costs continue, and how we capture the clinical trial costs, it will require significant investments going forwa | 17 |
| Q3FY22 | other | nan | I think this year we haven't given any specific guidance. | 17 |
| Q3FY22 | other | nan | So we should be able to launch this shortly. | 19 |
| Q3FY22 | revenue growth | nan | It's not a very large product, but the sales as well as the growth of the product are in public domain, so you should be able to see that. | 19 |
| Q3FY22 | other | nan | But this quarter has been much better and I think the next quarter we will be able to improve further. | 22 |
| Q3FY22 | other | nan | Hopefully, I think we should be able to break this drought of potential acquisitions that we've seen in last few years in next maybe one or two years. | 23 |
| Q4FY22 | other | nan | Our India formulations sales for the full year FY22 were Rs. 127,593 million recording a strong 23.4% growth over previous year. | 6 |
| Q4FY22 | other | nan | Our overall US business grew by 12% to US$ 1,526 million for the full year FY22 driven mainly by the strong performance of our specialty business. | 7 |
| Q4FY22 | other | nan | Our branded formulation revenues in Emerging Markets were at about US$ 905 million for the full year, up by about 16% year-on-year. | 8 |
| Q4FY22 | other | nan | We feel reasonably comfortable that we should be able to do quite well in these litigations. | 10 |
| Q4FY22 | other | nan | Our hope is to capitalize on that and to make this into a meaningful product for the specialty business going forward. | 11 |
| Q4FY22 | pricing | nan | I think hopefully; we should be able to offset some of the cost increases with our ability to take a price increase in the marketplace. | 17 |
| Q4FY22 | other | nan | So, to that extent, we expect India businesses to get adjusted for that growth. | 18 |
| Q4FY22 | other | nan | If I look at it from a medium to long-term perspective, I think growth will be driven by a combination of organically growing the products that we have, whereas | 18 |
| Q1FY23 | other | LOWERED | Lower R&D spending is basically a timing issue and we expect it will gain momentum and be in-line with our guidance in the coming quarters. | 7 |
| Q1FY23 | other | nan | As to the first part, internally, I am clear when we would be likely to launch, but on our calls, we don't give product wise details when exactly we are launchi | 14 |
| Q1FY23 | other | nan | We have not given any specific guidance, but we have no major investment. | 15 |
| Q1FY23 | pricing | nan | And as of today, as I understand that there are 25 companies which has launched the generic products and the pricing is in the range of Rs. 9-10 for 50 milligra | 16 |
| Q1FY23 | other | nan | So, at the outset, we want to clarify that we have not given any annual target or guidance of global specialty sales. | 17 |
| Q1FY23 | other | nan | As such, we have not given any guidance on any specific individual business. | 17 |
| Q1FY23 | other | nan | I think you should factor everything that we've given within our guidance. | 17 |
| Q1FY23 | other | nan | It's a mixture of how we expect all our businesses to perform, that will include specialty, generic, all markets. | 17 |
| Q1FY23 | other | nan | We also said at that time, that we are looking at products in the third wave of approvals, in the sense, that we want to be in time for the launch along with pa | 18 |
| Q1FY23 | other | nan | Hopefully, we should be able to close all these issues in 12-months. | 21 |
| Q1FY23 | other | nan | It's more an expectation of how Ilumya will grow, is part of our total guidance. | 22 |
| Q2FY23 | other | nan | With new indications expected in future, the current growth trajectory of Ilumya would be sustained. | 7 |
| Q2FY23 | capex | nan | With improving access coupled with geographical expansion into other markets, we expect Winlevi to continue to grow. | 7 |
| Q2FY23 | other | nan | I think we are on track to meet our obligations and launch. | 9 |
| Q2FY23 | margin | nan | Generally, we don't guide for EBITDA and margins, but broad guidance is that our focus would be to find a way to improve our overall profitability. | 10 |
| Q2FY23 | other | nan | And you will see that this is just a blip that is not to be expected to go into the future. | 11 |
| Q2FY23 | other | nan | All I will say is what I said earlier, we are on track as for whatever we have agreed to with the innovator, and fingers crossed. | 13 |
| Q2FY23 | other | nan | Yes, I think you are right, even though on absolute terms, it is going up, in percentage terms, it’s not as per the guidance. | 13 |
| Q2FY23 | other | nan | I think we have guided that we expect the R&D spending in the next two quarters to go up. | 13 |
| Q2FY23 | other | nan | So, I think we are trying to help you understand without giving specific guidance. | 14 |
| Q2FY23 | other | nan | On a lighter side, I think Kirti will respond, but maybe it will help me if you can do his review from next quarter. | 14 |
| Q2FY23 | other | nan | So, I think the idea is to find a way to increase and that's also possibly the reason for the delta between our guidance and our actual spend. | 16 |
| Q2FY23 | other | nan | However, as we said that we are not giving any specific guidance on other expenses or margins. | 17 |
| Q2FY23 | other | nan | And I think we are on track to do that. | 18 |
| Q2FY23 | other | nan | So, we don't wish to give any specific guidance on up to which period we expect exclusivity. | 20 |
| Q2FY23 | other | nan | I think next quarter onwards, we will see increase as we used to that's my personal sense. | 21 |
| Q2FY23 | other | nan | So, I think our guidance is 6% to 8%. | 21 |
| Q2FY23 | other | nan | And I think we are not changing the guidance at this point. | 21 |
| Q2FY23 | other | nan | When you say target market, you are referring to doctors? | 21 |
| Q2FY23 | other | nan | So, as we said earlier, no, we are not giving any guidance on this, but based on what you said we should all go on long holiday so that business will take care | 22 |
| Q2FY23 | other | nan | And as per our internal working also, it is also expected to go up as we move forward. | 24 |
| Q2FY23 | other | nan | Abhishek has joined us as Head of Investor Relations and will be taking over the IR responsibilities from the next quarter onwards. | 24 |
| Q3FY23 | other | nan | We should be able to update the status of this trial in our next call. | 7 |
| Q3FY23 | other | nan | The R&D investments have increased compared to Q2, and we expect a continued ramp-up of the same. | 7 |
| Q3FY23 | other | nan | R&D investments are likely to increase, both for our specialty and generic businesses. | 7 |
| Q3FY23 | other | nan | Yes, I think we have guided that we had challenges in terms of ramping up the clinical studies because of the COVID, and subsequently, because of the war in Rus | 9 |
| Q3FY23 | other | nan | It's not the next quarter, it will get addressed. | 10 |
| Q3FY23 | other | nan | And there is a significant overlap between the HCPs that we meet and the HCPs who are likely to be treating | 12 |
| Q3FY23 | other | nan | That guidance we will give next year. because I think we will look at the -- all the products in different stages of development, like what I also shared is, we | 13 |
| Q3FY23 | other | MAINTAINED | And I think we had made some changes to our co-pay plan and then we had improvement in the access, so, I'm pretty confident that, the growth trajectory we will | 14 |
| Q3FY23 | other | nan | We shared at the time of sharing the information about Halol, is that based on this, we expect the impact to be less than 3% of the total sales. | 20 |
| Q3FY23 | other | nan | And we are not changing or revising our guidance because of this. | 20 |
| Q3FY23 | other | nan | The transaction has to close, which we expect to close probably in the first quarter of this calendar year. | 22 |
| Q3FY23 | other | nan | So Abhay, I think we've given some guidance in the past? | 22 |
| Q3FY23 | other | nan | We are on track for launch. | 23 |
| Q3FY23 | other | nan | But we don't give guidance beyond the next year. | 24 |
| Q3FY23 | other | nan | We believe that we've now put in place an appropriate focus and structure so that we should be able to meet the expectation of the agencies. | 26 |
| Q3FY23 | other | nan | So hopefully, I think with the rationalization of valuation, we should be able to do something. | 29 |
| Q4FY23 | other | nan | Let me take you through the performance of our India business: Our India formulations sales for the full year FY23 were Rs.136,031 million, recording 6.6% growt | 6 |
| Q4FY23 | other | nan | Our overall US business grew by 10.3% to US$1,684 million for the full year FY23, driven mainly by the strong performance of our specialty business. | 7 |
| Q4FY23 | other | nan | Our branded formulations revenues in emerging markets were at about US$983 million for the full year, up by about 8.6% year-on-year. | 7 |
| Q4FY23 | other | nan | No, I think our current guidance is that we should be filing the product by second quarter, which I think because of the FDA hold on 12 milligram, we are relook | 9 |
| Q4FY23 | other | nan | And based on that, once we have clarity we will give you some guidance as to by what time we can come to market. | 9 |
| Q4FY23 | other | nan | We've already received EIR and we believe that in a gradual and phased manner, we should be able to start selling products out of | 10 |
| Q4FY23 | other | nan | As we shared in the readout, it will normalize as a percentage of sales going forward. | 10 |
| Q4FY23 | other | LOWERED | No, I think we are on the lower end of the overall R&D guidance. | 13 |
| Q4FY23 | other | nan | Unfortunately, we couldn't do that this quarter, we will start doing it from next quarter as a part of readout only. | 14 |
| Q4FY23 | other | nan | So, I mean, getting coverage for any product is always a challenge and it's a challenge that we are expecting to meet. | 21 |
| Q4FY23 | other | nan | So, that's factored in our guidance. | 22 |
| Q4FY23 | other | nan | It's an achievable guidance. | 22 |
| Q4FY23 | other | nan | So, we are not giving a separate guidance on that, because we don't know by what time, what products we want to bring back and we might be able to protect the e | 22 |
| Q4FY23 | margin | nan | I think we don't guide for overall profitability because there are so many moving parts. | 23 |
| Q1FY24 | other | nan | So if I see the underlying base business and the prescription trends of all our major products other than Levulan, I think we are on the right trajectory. | 7 |
| Q1FY24 | other | nan | I think as on today, you should consider the full year guidance. | 8 |
| Q1FY24 | other | nan | So in our Q4 call, we already said that the sales and distribution in previous calls that these costs have some catch up and unlikely to escalate on the same pa | 8 |
| Q1FY24 | revenue growth | nan | There may be sales-related growth in these expenses going forward. | 8 |
| Q1FY24 | other | nan | But also since it's an additional indication, in the other geographies, we should be able to get that filed in a relatively short time. | 12 |
| Q1FY24 | other | nan | Shanghvi already mentioned that we're working towards the various clinical trials of various candidates, what we have, and we are on track to achieve R&D guidan | 16 |
| Q1FY24 | other | nan | Concert is part of our R&D guidance. | 16 |
| Q1FY24 | other | nan | As of now, for our range of products, I haven't seen any big opportunities, which can swing the pendulum, so to say. | 20 |
| Q2FY24 | other | nan | I think as on today, you should presume the guidance. | 7 |
| Q2FY24 | other | nan | I think that should be the focus. | 8 |
| Q2FY24 | other | nan | The return we expect to normalcy will be gradual, although we are not giving any time frame to normalization. | 9 |
| Q2FY24 | other | nan | No, I think the reason why we don't share detailing because we don't want to give future guidance on something that can change at many points of time. | 13 |
| Q2FY24 | other | MAINTAINED | So because we try and see that whatever guidance we give for the year, we are able to maintain and deliver. | 13 |
| Q2FY24 | other | nan | So I would say that we are exploring new areas but without diluting our focus on our core prescription business which we see a good potential going forward. | 14 |
| Q3FY24 | other | nan | So I mean there will be additional investment based on the trajectory of the products that you see in the budgets that we take for next year. | 6 |
| Q3FY24 | other | nan | So what we have said is that the Phase II study on GL0034 will start in the second half of next year. | 10 |
| Q3FY24 | other | nan | But it's going to be an important market for Ilumya going forward. | 10 |
| Q3FY24 | other | nan | So when we share the next year's guidance, we will share the R&D guidance also. | 11 |
| Q3FY24 | other | nan | So hopefully, we will touch the low end of the guidance. | 11 |
| Q3FY24 | other | nan | So there's no need for us to, at this point of time, revise the guidance because it's not something where we are consistently significantly higher. | 14 |
| Q3FY24 | other | nan | And looking at some of the corrections which have taken place, I think we see some interesting opportunity that we should be able to work on. | 14 |
| Q3FY24 | other | nan | Your question on next year is very difficult for us to predict what the market will be next year. | 15 |
| Q4FY24 | other | nan | Our India formulation sales for the full year FY '24 were INR148,893 million, recording 9.5% growth over previous year. | 4 |
| Q4FY24 | other | nan | Our overall U.S. business grew by 10.1% to $1,854 million for the full year FY'24. | 5 |
| Q4FY24 | other | nan | Our branded formulation revenues in Emerging Markets were $1.041 billion for the full year, up by 5.9% year-on-year. | 5 |
| Q4FY24 | other | nan | But otherwise, the overall guidance is a consolidated guidance for all businesses. | 7 |
| Q4FY24 | other | nan | So we are on track to launch it post the PDUFA date. | 8 |
| Q4FY24 | other | nan | But we are on track as of now. | 8 |
| Q4FY24 | other | nan | Now we have multiple patents and we feel that we should be able to protect the product for a much longer period of time. | 10 |
| Q4FY24 | revenue growth | nan | From the overall perspective for FY '25 outlook, we have given the revenue guidance. | 11 |
| Q4FY24 | margin | nan | At this point of time, we are not giving any EBITDA margin guidance for FY '25. | 11 |
| Q4FY24 | other | nan | Secondly, I think over a period of time, we should be able to get our new indication of psoriatic arthritis. | 13 |
| Q4FY24 | other | nan | We are not giving any guidance on margins at this point of time. | 13 |
| Q4FY24 | other | nan | And in Europe, if you get good reimbursement and you have good marketing infrastructure, you should be able to at least successfully ensure that the product ben | 14 |
| Q4FY24 | other | nan | So the overall guidance, which Mr. | 15 |
| Q4FY24 | other | nan | We believe that increased business that we will get, we should be able to adjust for the increased marketing spend, except in some onetime costs. | 17 |
| Q4FY24 | other | nan | So we already mentioned that tax expense should be seen on an annual basis. | 17 |
| Q4FY24 | other | nan | And it's likely to inch up as we move forward year after year. | 17 |
| Q4FY24 | other | nan | So our focus is to find a way to give you a guidance for this year, and our effort would be to see that we meet the guidance. | 18 |
| Q4FY24 | other | nan | And I think the overall guidance we have presumes in fact of the current challenges that we have in the facilities. | 18 |
| Q1FY25 | other | nan | So, I think the idea is that once we are clear, which should be shortly, we will request FDA for a re-audit of the facility. | 9 |
| Q1FY25 | other | nan | It is already there, but it is expected to go up when we actually launch the product there. | 10 |
| Q1FY25 | other | nan | We have shared the, what you call details about when we expect to file for this product. | 12 |
Claims reconciled to filings
| Quarter | Metric | Claimed | Kind | Anchor | Anchor value | Verdict | Source |
|---|---|---|---|---|---|---|---|
| Q4FY21 | operating margin | 23.2 % | ratio | EBITDA / total income | 0.25 | CLOSE_WITHIN_10PCT | Date_20210602_Sun Pharmaceutic p5 |
| Q4FY21 | operating margin | 23.2 % | ratio | EBITDA / total income | 0.25 | CLOSE_WITHIN_10PCT | Date_20210602_Sun Pharmaceutic p6 |
| Q4FY21 | operating margin | 24.5 % | ratio | EBITDA / total income | 0.25 | CLOSE_WITHIN_10PCT | Date_20210602_Sun Pharmaceutic p6 |
| Q1FY22 | operating margin | 28.7 % | ratio | EBITDA / total income | 0.30 | CLOSE_WITHIN_10PCT | Date_20210806_Sun Pharmaceutic p5 |
| Q1FY22 | operating margin | 28.7 % | ratio | EBITDA / total income | 0.30 | CLOSE_WITHIN_10PCT | Date_20210806_Sun Pharmaceutic p5 |
| Q2FY22 | operating margin | 26.8 % | ratio | EBITDA / total income | 0.29 | CLOSE_WITHIN_10PCT | Date_20211111_Sun Pharmaceutic p4 |
| Q2FY22 | operating margin | 27.7 % | ratio | EBITDA / total income | 0.29 | CLOSE_WITHIN_10PCT | Date_20211111_Sun Pharmaceutic p6 |
| Q3FY22 | revenue growth | 21 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220203_Sun Pharmaceutic p4 |
| Q3FY22 | operating margin | 26.1 % | ratio | EBIT / core revenue | 0.25 | CLOSE_WITHIN_10PCT | Date_20220203_Sun Pharmaceutic p4 |
| Q3FY22 | revenue growth | 3 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220203_Sun Pharmaceutic p5 |
| Q3FY22 | operating margin | 27.2 % | ratio | EBIT / core revenue | 0.25 | CLOSE_WITHIN_10PCT | Date_20220203_Sun Pharmaceutic p5 |
| Q3FY22 | revenue growth | 4 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220203_Sun Pharmaceutic p6 |
| Q3FY22 | revenue growth | 6 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220203_Sun Pharmaceutic p7 |
| Q4FY22 | operating margin | 26.5 % | ratio | EBITDA / core revenue | 0.26 | CLOSE_WITHIN_10PCT | Date_20220602_Sun Pharmaceutic p5 |
| Q4FY22 | operating margin | 24.3 % | ratio | EBITDA / total income | 0.26 | CLOSE_WITHIN_10PCT | Date_20220602_Sun Pharmaceutic p6 |
| Q4FY22 | revenue growth | 2.3 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220602_Sun Pharmaceutic p6 |
| Q4FY22 | revenue growth | 5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220602_Sun Pharmaceutic p7 |
| Q1FY23 | revenue growth | 10 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220803_Sun Pharmaceutic p4 |
| Q1FY23 | revenue growth | 29 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220803_Sun Pharmaceutic p4 |
| Q1FY23 | operating margin | 26.8 % | ratio | EBITDA / total income | 0.27 | AGREES | Date_20220803_Sun Pharmaceutic p4 |
| Q1FY23 | revenue growth | 2 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20220803_Sun Pharmaceutic p4 |
| Q1FY23 | operating margin | 26.8 % | ratio | EBITDA / total income | 0.27 | AGREES | Date_20220803_Sun Pharmaceutic p5 |
| Q2FY23 | revenue growth | 27.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20221105_Sun Pharmaceutic p4 |
| Q2FY23 | operating margin | 27 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20221105_Sun Pharmaceutic p4 |
| Q2FY23 | revenue growth | 12.4 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20221105_Sun Pharmaceutic p4 |
| Q2FY23 | operating margin | 27 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20221105_Sun Pharmaceutic p5 |
| Q2FY23 | operating margin | 26.9 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20221105_Sun Pharmaceutic p5 |
| Q3FY23 | revenue growth | 28.4 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230201_Sun Pharmaceutic p3 |
| Q3FY23 | operating profit / EBITDA | 30,037 million | money | derived EBITDA | 31,776,000,000.00 | CLOSE_WITHIN_10PCT | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | operating margin | 26.7 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | revenue growth | 15.2 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | profit after tax | 21,660 million | money | PROFIT_AFTER_TAX | 21,807,500,000.00 | AGREES | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | operating profit / EBITDA | 30,037 million | money | derived EBITDA | 31,776,000,000.00 | CLOSE_WITHIN_10PCT | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | operating margin | 26.7 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | profit after tax | 21,660 million | money | PROFIT_AFTER_TAX | 21,807,500,000.00 | AGREES | Date_20230201_Sun Pharmaceutic p5 |
| Q3FY23 | profit after tax | 64,891 million | money | PROFIT_AFTER_TAX | 21,807,500,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20230201_Sun Pharmaceutic p6 |
| Q3FY23 | revenue | 12.5 million | money | REVENUE_FROM_OPERATIONS | 112,409,700,000.00 | DIVERGES | Date_20230201_Sun Pharmaceutic p7 |
| Q4FY23 | revenue growth | 31.7 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230531_Sun Pharmaceutic p4 |
| Q4FY23 | operating profit / EBITDA | 116,468 million | money | derived EBITDA | 31,754,100,000.00 | DIVERGES | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | operating margin | 26.5 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | profit after tax | 86,450 million | money | PROFIT_AFTER_TAX | 19,829,000,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | profit after tax | 84,736 million | money | PROFIT_AFTER_TAX | 19,829,000,000.00 | DIVERGES | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | operating profit / EBITDA | 28,021 million | money | derived EBITDA | 31,754,100,000.00 | DIVERGES | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | operating margin | 25.6 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | revenue growth | 19.7 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | profit after tax | 19,845 million | money | PROFIT_AFTER_TAX | 19,829,000,000.00 | AGREES | Date_20230531_Sun Pharmaceutic p5 |
| Q4FY23 | operating margin | 25.6 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20230531_Sun Pharmaceutic p6 |
| Q4FY23 | profit after tax | 19,845 million | money | PROFIT_AFTER_TAX | 19,829,000,000.00 | AGREES | Date_20230531_Sun Pharmaceutic p6 |
| Q4FY23 | revenue growth | 2.1 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230531_Sun Pharmaceutic p6 |
| Q1FY24 | revenue | 33,318 million | money | REVENUE_FROM_OPERATIONS | 119,408,400,000.00 | DIVERGES | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | operating profit / EBITDA | 33,318 million | money | derived EBITDA | 35,362,100,000.00 | CLOSE_WITHIN_10PCT | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | operating margin | 27.9 % | ratio | EBITDA / total income | 0.29 | CLOSE_WITHIN_10PCT | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | revenue growth | 15.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | profit after tax | 23,454 million | money | PROFIT_AFTER_TAX | 20,056,500,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | profit after tax | 20,225 million | money | PROFIT_AFTER_TAX | 20,056,500,000.00 | AGREES | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | operating margin | 27.8 % | ratio | EBITDA / total income | 0.29 | CLOSE_WITHIN_10PCT | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | profit after tax | 20,225 million | money | PROFIT_AFTER_TAX | 20,056,500,000.00 | AGREES | Date_20230809_Sun Pharmaceutic p4 |
| Q1FY24 | revenue growth | 6.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20230809_Sun Pharmaceutic p5 |
| Q2FY24 | operating margin | 26.1 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | revenue | 31,794 million | money | REVENUE_FROM_OPERATIONS | 121,924,100,000.00 | DIVERGES | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | operating profit / EBITDA | 31,794 million | money | derived EBITDA | 34,729,900,000.00 | CLOSE_WITHIN_10PCT | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | revenue growth | 7.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | operating margin | 26.1 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | profit after tax | 23,755 million | money | PROFIT_AFTER_TAX | 23,851,000,000.00 | AGREES | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | operating profit / EBITDA | 65,112 million | money | derived EBITDA | 34,729,900,000.00 | DIFFERENT_BASIS_LIKELY | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | operating margin | 27 % | ratio | EBITDA / total income | 0.28 | CLOSE_WITHIN_10PCT | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | profit after tax | 47,209 million | money | PROFIT_AFTER_TAX | 23,851,000,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | profit after tax | 43,981 million | money | PROFIT_AFTER_TAX | 23,851,000,000.00 | DIFFERENT_BASIS_LIKELY | Date_20231108_Sun Pharmaceutic p4 |
| Q2FY24 | revenue growth | 9.4 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20231108_Sun Pharmaceutic p5 |
| Q3FY24 | operating margin | 28.1 % | ratio | EBITDA / total income | 0.30 | CLOSE_WITHIN_10PCT | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | profit after tax | 25,936 million | money | PROFIT_AFTER_TAX | 25,605,400,000.00 | AGREES | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | profit after tax | 25,238 million | money | PROFIT_AFTER_TAX | 25,605,400,000.00 | AGREES | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | operating profit / EBITDA | 99,880 million | money | derived EBITDA | 37,270,300,000.00 | DIVERGES | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | operating margin | 27.4 % | ratio | EBITDA / total income | 0.30 | CLOSE_WITHIN_10PCT | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | profit after tax | 73,145 million | money | PROFIT_AFTER_TAX | 25,605,400,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | profit after tax | 69,218 million | money | PROFIT_AFTER_TAX | 25,605,400,000.00 | DIVERGES | Date_20240206_Sun Pharmaceutic p4 |
| Q3FY24 | revenue growth | 12.9 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20240206_Sun Pharmaceutic p5 |
| Q4FY24 | profit after tax | 100,707 million | money | PROFIT_AFTER_TAX | 26,587,400,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | profit after tax | 95,764 million | money | PROFIT_AFTER_TAX | 26,587,400,000.00 | DIVERGES | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | revenue | 30,352 million | money | REVENUE_FROM_OPERATIONS | 119,829,000,000.00 | DIVERGES | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | operating profit / EBITDA | 30,352 million | money | derived EBITDA | 36,410,900,000.00 | DIVERGES | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | operating margin | 25.3 % | ratio | EBIT / core revenue | 0.25 | AGREES | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | profit after tax | 27,562 million | money | PROFIT_AFTER_TAX | 26,587,400,000.00 | CLOSE_WITHIN_10PCT | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | profit after tax | 26,546 million | money | PROFIT_AFTER_TAX | 26,587,400,000.00 | AGREES | Date_20240529_Sun Pharmaceutic p4 |
| Q4FY24 | revenue growth | 7.8 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20240529_Sun Pharmaceutic p5 |
| Q1FY25 | operating margin | 28.5 % | ratio | EBIT / core revenue | 0.28 | CLOSE_WITHIN_10PCT | Date_20240807_Sun Pharmaceutic p4 |
| Q1FY25 | revenue growth | 8.8 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20240807_Sun Pharmaceutic p5 |
| Q2FY25 | operating margin | 29.6 % | ratio | EBITDA / total income | 0.31 | CLOSE_WITHIN_10PCT | Date_20241104_Sun Pharmaceutic p4 |
| Q2FY25 | operating margin | 29.1 % | ratio | EBIT / core revenue | 0.28 | CLOSE_WITHIN_10PCT | Date_20241104_Sun Pharmaceutic p4 |
| Q2FY25 | revenue growth | 3.2 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20241104_Sun Pharmaceutic p5 |
| Q3FY25 | profit after tax | 32,196 million | money | PROFIT_AFTER_TAX | 29,129,800,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20250206_Sun Pharmaceutic p4 |
| Q3FY25 | profit after tax | 29,034 million | money | PROFIT_AFTER_TAX | 29,129,800,000.00 | AGREES | Date_20250206_Sun Pharmaceutic p4 |
| Q3FY25 | operating profit / EBITDA | 115,556 million | money | derived EBITDA | 44,746,400,000.00 | DIFFERENT_BASIS_LIKELY | Date_20250206_Sun Pharmaceutic p4 |
| Q3FY25 | operating margin | 29.2 % | ratio | EBIT / core revenue | 0.28 | CLOSE_WITHIN_10PCT | Date_20250206_Sun Pharmaceutic p4 |
| Q3FY25 | profit after tax | 90,953 million | money | PROFIT_AFTER_TAX | 29,129,800,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20250206_Sun Pharmaceutic p4 |
| Q3FY25 | profit after tax | 87,792 million | money | PROFIT_AFTER_TAX | 29,129,800,000.00 | DIVERGES | Date_20250206_Sun Pharmaceutic p4 |
| Q3FY25 | revenue growth | 10.1 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20250206_Sun Pharmaceutic p5 |
| Q4FY25 | operating margin | 29 % | ratio | EBIT / core revenue | 0.28 | CLOSE_WITHIN_10PCT | Date_20250529_Sun Pharmaceutic p3 |
| Q4FY25 | operating margin | 28.7 % | ratio | EBIT / core revenue | 0.28 | AGREES | Date_20250529_Sun Pharmaceutic p4 |
| Q4FY25 | revenue growth | 4.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20250529_Sun Pharmaceutic p6 |
| Q1FY26 | operating margin | 31.1 % | ratio | EBIT / core revenue | 0.29 | CLOSE_WITHIN_10PCT | Date_20250806_Sun Pharmaceutic p4 |
| Q1FY26 | revenue growth | 5.1 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20250806_Sun Pharmaceutic p5 |
| Q1FY26 | revenue growth | 15.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20250806_Sun Pharmaceutic p5 |
| Q2FY26 | operating profit / EBITDA | 45,271 million | money | derived EBITDA | 49,969,700,000.00 | CLOSE_WITHIN_10PCT | Date_20251111_Sun Pharmaceutic p3 |
| Q2FY26 | operating margin | 31.3 % | ratio | EBIT / core revenue | 0.29 | CLOSE_WITHIN_10PCT | Date_20251111_Sun Pharmaceutic p3 |
| Q2FY26 | profit after tax | 31,180 million | money | PROFIT_AFTER_TAX | 31,249,500,000.00 | AGREES | Date_20251111_Sun Pharmaceutic p3 |
| Q2FY26 | operating profit / EBITDA | 88,287 million | money | derived EBITDA | 49,969,700,000.00 | DIFFERENT_BASIS_LIKELY | Date_20251111_Sun Pharmaceutic p4 |
| Q2FY26 | operating margin | 31.2 % | ratio | EBIT / core revenue | 0.29 | CLOSE_WITHIN_10PCT | Date_20251111_Sun Pharmaceutic p4 |
| Q2FY26 | profit after tax | 61,141 million | money | PROFIT_AFTER_TAX | 31,249,500,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20251111_Sun Pharmaceutic p4 |
| Q2FY26 | revenue growth | 10.9 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20251111_Sun Pharmaceutic p5 |
| Q2FY26 | revenue growth | 17.7 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20251111_Sun Pharmaceutic p5 |
| Q3FY26 | operating profit / EBITDA | 49,485 million | money | derived EBITDA | 55,273,300,000.00 | DIVERGES | Date_20260204_Sun Pharmaceutic p4 |
| Q3FY26 | operating margin | 31.9 % | ratio | EBIT / core revenue | 0.31 | CLOSE_WITHIN_10PCT | Date_20260204_Sun Pharmaceutic p4 |
| Q3FY26 | profit after tax | 33,688 million | money | PROFIT_AFTER_TAX | 33,811,700,000.00 | AGREES | Date_20260204_Sun Pharmaceutic p4 |
| Q3FY26 | profit after tax | 35,367 million | money | PROFIT_AFTER_TAX | 33,811,700,000.00 | CLOSE_WITHIN_10PCT | Date_20260204_Sun Pharmaceutic p4 |
| Q3FY26 | operating profit / EBITDA | 1,37,772 million | money | derived EBITDA | 55,273,300,000.00 | DIFFERENT_BASIS_LIKELY | Date_20260204_Sun Pharmaceutic p5 |
| Q3FY26 | operating margin | 31.4 % | ratio | EBIT / core revenue | 0.31 | AGREES | Date_20260204_Sun Pharmaceutic p5 |
| Q3FY26 | profit after tax | 96,508 million | money | PROFIT_AFTER_TAX | 33,811,700,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20260204_Sun Pharmaceutic p5 |
| Q3FY26 | revenue growth | 21.6 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20260204_Sun Pharmaceutic p7 |
| Q3FY26 | revenue growth | 14.5 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20260204_Sun Pharmaceutic p7 |
| Q4FY26 | revenue growth | 14.4 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20260505_Sun Pharmaceutic p5 |
| Q4FY26 | operating margin | 30 % | ratio | EBITDA / core revenue | 0.30 | AGREES | Date_20260505_Sun Pharmaceutic p5 |
| Q4FY26 | operating profit / EBITDA | 39,542 million | money | derived EBITDA | 44,127,000,000.00 | DIVERGES | Date_20260529_Sun Pharmaceutic p4 |
| Q4FY26 | operating margin | 27.1 % | ratio | EBITDA / total income | 0.29 | CLOSE_WITHIN_10PCT | Date_20260529_Sun Pharmaceutic p4 |
| Q4FY26 | profit after tax | 27,140 million | money | PROFIT_AFTER_TAX | 27,096,600,000.00 | AGREES | Date_20260529_Sun Pharmaceutic p4 |
| Q4FY26 | operating profit / EBITDA | 1,77,314 million | money | derived EBITDA | 44,127,000,000.00 | DIVERGES | Date_20260529_Sun Pharmaceutic p4 |
| Q4FY26 | operating margin | 30.3 % | ratio | EBITDA / core revenue | 0.30 | AGREES | Date_20260529_Sun Pharmaceutic p4 |
| Q4FY26 | profit after tax | 1,24,015 million | money | PROFIT_AFTER_TAX | 27,096,600,000.00 | ADJUSTED_MEASURE_NOT_STATUTORY | Date_20260529_Sun Pharmaceutic p4 |
| Q4FY26 | revenue growth | 17.4 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20260529_Sun Pharmaceutic p5 |
| Q4FY26 | revenue growth | 10 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20260529_Sun Pharmaceutic p6 |
| Q1FY27 | operating profit / EBITDA | 44,177 million | money | derived EBITDA | 51,412,900,000.00 | DIVERGES | Date_20260806_Sun Pharmaceutic p4 |
| Q1FY27 | operating margin | 28.9 % | ratio | EBIT / core revenue | 0.29 | AGREES | Date_20260806_Sun Pharmaceutic p4 |
| Q1FY27 | profit after tax | 28,948 million | money | PROFIT_AFTER_TAX | 29,012,300,000.00 | AGREES | Date_20260806_Sun Pharmaceutic p4 |
| Q1FY27 | revenue growth | 4.2 % | ratio | not comparable without the prior year quarter in scope | nan | NO_ANCHOR | Date_20260806_Sun Pharmaceutic p6 |
| nan | operating margin | 30 % | ratio | nan | nan | NO_QUARTER_IN_FILENAME | 6fb0611b-17c4-4e4b-8730-63f760 p8 |
SUNPHARMA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,849.90 |
| 52-week range | 1586.7 – 2001.1 |
| Return 1M | -3.75% |
| Return 3M | -0.69% |
| Return 1Y | 13.69% |
| Return 3Y | 64.57% |
| Return 5Y | 140.11% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 15,300.00 |
| Other income | 724.00 |
| Total income | 16,024.00 |
| Cost of materials consumed | 2,026.00 |
| Purchases of stock-in-trade | 1,020.00 |
| Changes in inventories | -83.00 |
| Employee benefit expense | 3,227.00 |
| Finance costs | 100.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.54 | 0.00 |
| institutions foreign | 0.15 | -0.01 |
| institutions domestic | 0.22 | 0.01 |
| mutual funds | 0.13 | 0.01 |
| public | 0.46 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 23 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 10,952.00 | 11,241.00 | 10,931.00 | 11,941.00 | 12,192.00 | 12,381.00 | 11,983.00 | 12,653.00 | 13,291.00 | 13,675.00 | 12,959.00 | 13,851.00 | 14,478.00 | 15,521.00 | 14,612.00 | 15,300.00 |
| Other income | 85.00 | 174.00 | 373.00 | 204.00 | 294.00 | 250.00 | 606.00 | 533.00 | 354.00 | 466.00 | 613.00 | 464.00 | 470.00 | 579.00 | 458.00 | 724.00 |
| Total income | 11,038.00 | 11,415.00 | 11,304.00 | 12,145.00 | 12,486.00 | 12,631.00 | 12,589.00 | 13,185.00 | 13,645.00 | 14,141.00 | 13,572.00 | 14,316.00 | 14,948.00 | 16,099.00 | 15,070.00 | 16,024.00 |
| Cost of materials consumed | 2,017.00 | 1,860.00 | 1,900.00 | 1,852.00 | 1,665.00 | 1,710.00 | 1,677.00 | 1,557.00 | 1,639.00 | 1,408.00 | 1,845.00 | 1,772.00 | 1,622.00 | 1,813.00 | 2,182.00 | 2,026.00 |
| Purchases of stock-in-trade | 881.00 | 887.00 | 892.00 | 680.00 | 1,007.00 | 796.00 | 983.00 | 997.00 | 875.00 | 1,239.00 | 1,037.00 | 1,048.00 | 1,088.00 | 922.00 | 753.00 | 1,020.00 |
| Changes in inventories | -190.00 | 57.00 | -542.00 | 226.00 | 115.00 | 231.00 | -279.00 | 121.00 | 180.00 | 94.00 | -245.00 | -5.00 | 273.00 | 209.00 | -135.00 | -83.00 |
| Employee benefit expense | 2,005.00 | 2,037.00 | 2,180.00 | 2,402.00 | 2,364.00 | 2,363.00 | 2,299.00 | 2,455.00 | 2,478.00 | 2,552.00 | 2,489.00 | 2,802.00 | 2,765.00 | 2,892.00 | 2,960.00 | 3,227.00 |
| Finance costs | 19.00 | 46.00 | 93.00 | 81.00 | 49.00 | 35.00 | 74.00 | 62.00 | 69.00 | 52.00 | 49.00 | 75.00 | 100.00 | 78.00 | 86.00 | 100.00 |
| Depreciation and amortisation | 610.00 | 660.00 | 672.00 | 651.00 | 633.00 | 622.00 | 650.00 | 655.00 | 626.00 | 631.00 | 664.00 | 701.00 | 730.00 | 732.00 | 775.00 | 739.00 |
| Other expenses | 3,283.00 | 3,397.00 | 3,699.00 | 3,449.00 | 3,862.00 | 3,804.00 | 4,268.00 | 3,915.00 | 4,181.00 | 4,374.00 | 4,117.00 | 3,933.00 | 4,204.00 | 4,735.00 | 4,896.00 | 4,692.00 |
| Total expenses | 8,625.00 | 8,943.00 | 8,893.00 | 9,341.00 | 9,695.00 | 9,561.00 | 9,672.00 | 9,762.00 | 10,048.00 | 10,349.00 | 9,956.00 | 10,325.00 | 10,781.00 | 11,383.00 | 11,519.00 | 11,721.00 |
| Profit before exceptional items and tax | 2,412.00 | 2,471.00 | 2,411.00 | 2,804.00 | 2,791.00 | 3,070.00 | 2,917.00 | 3,424.00 | 3,598.00 | 3,793.00 | 3,616.00 | 3,991.00 | 4,168.00 | 4,717.00 | 3,551.00 | 4,303.00 |
| Exceptional items | 0.00 | 0.00 | -171.00 | -323.00 | 0.00 | -70.00 | -102.00 | 0.00 | 0.00 | -316.00 | -362.00 | -818.00 | 0.00 | -489.00 | 0.00 | -204.00 |
| Profit before tax | 2,412.00 | 2,471.00 | 2,240.00 | 2,481.00 | 2,791.00 | 3,000.00 | 2,816.00 | 3,424.00 | 3,598.00 | 3,476.00 | 3,254.00 | 3,173.00 | 4,168.00 | 4,227.00 | 3,551.00 | 4,099.00 |
| Current tax | 152.00 | 283.00 | 223.00 | 468.00 | 390.00 | 432.00 | 149.00 | 552.00 | 567.00 | 559.00 | 1,094.00 | 870.00 | 1,031.00 | 826.00 | 828.00 | 1,188.00 |
| Deferred tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax expense | 152.00 | 283.00 | 223.00 | 468.00 | 390.00 | 432.00 | 149.00 | 552.00 | 567.00 | 559.00 | 1,094.00 | 870.00 | 1,031.00 | 826.00 | 828.00 | 1,188.00 |
| Profit for the period | 2,256.00 | 2,181.00 | 1,983.00 | 2,006.00 | 2,385.00 | 2,561.00 | 2,659.00 | 2,861.00 | 3,037.00 | 2,913.00 | 2,154.00 | 2,293.00 | 3,125.00 | 3,381.00 | 2,710.00 | 2,901.00 |
| Profit attributable to owners | 2,262.00 | 2,166.00 | 1,984.00 | 2,023.00 | 2,376.00 | 2,524.00 | 2,655.00 | 2,836.00 | 3,040.00 | 2,903.00 | 2,150.00 | 2,279.00 | 3,118.00 | 3,369.00 | 2,714.00 | 2,895.00 |
| Profit attributable to non-controlling interests | -6.00 | 15.00 | -2.00 | -17.00 | 10.00 | 37.00 | 4.00 | 25.00 | -3.00 | 10.00 | 4.00 | 14.00 | 7.00 | 12.00 | -4.00 | 6.00 |
| Other comprehensive income | 725.00 | 748.00 | -161.00 | 217.00 | 219.00 | 425.00 | 281.00 | 41.00 | 418.00 | 118.00 | 335.00 | 127.00 | 1,415.00 | 781.00 | 1,503.00 | 1,509.00 |
| Total comprehensive income | 2,980.00 | 2,929.00 | 1,822.00 | 2,222.00 | 2,604.00 | 2,985.00 | 2,940.00 | 2,902.00 | 3,455.00 | 3,031.00 | 2,489.00 | 2,420.00 | 4,540.00 | 4,162.00 | 4,213.00 | 4,410.00 |
| Earnings per share, basic | 9.40 | 9.00 | 8.30 | 8.40 | 9.90 | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 | 9.00 | 9.50 | 13.00 | 14.00 | 11.30 | 12.10 |
| Earnings per share, diluted | 9.40 | 9.00 | 8.30 | 8.40 | 9.90 | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 | 9.00 | 9.50 | 13.00 | 14.00 | 11.30 | 12.10 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 29,066.00 | 32,838.00 | 33,498.00 | 38,654.00 | 43,886.00 | 48,497.00 | 52,578.00 | 58,462.00 |
| Other income | 1,025.00 | 636.00 | 836.00 | 922.00 | 635.00 | 1,354.00 | 1,965.00 | 1,972.00 |
| Total income | 30,091.00 | 33,473.00 | 34,334.00 | 39,576.00 | 44,520.00 | 49,851.00 | 54,543.00 | 60,434.00 |
| Cost of materials consumed | 5,783.00 | 5,515.00 | 6,153.00 | 7,049.00 | 7,778.00 | 6,904.00 | 6,449.00 | 7,389.00 |
| Purchases of stock-in-trade | 2,519.00 | 3,414.00 | 3,175.00 | 3,410.00 | 3,572.00 | 3,466.00 | 4,148.00 | 3,812.00 |
| Changes in inventories | -433.00 | 301.00 | -638.00 | -108.00 | -687.00 | 292.00 | 150.00 | 343.00 |
| Employee benefit expense | 5,967.00 | 6,362.00 | 6,862.00 | 7,301.00 | 8,296.00 | 9,429.00 | 9,973.00 | 11,419.00 |
| Finance costs | 555.00 | 303.00 | 141.00 | 127.00 | 172.00 | 238.00 | 231.00 | 339.00 |
| Depreciation and amortisation | 1,753.00 | 2,053.00 | 2,080.00 | 2,144.00 | 2,529.00 | 2,557.00 | 2,575.00 | 2,938.00 |
| Other expenses | 8,922.00 | 10,255.00 | 9,454.00 | 10,604.00 | 13,281.00 | 15,382.00 | 16,586.00 | 17,768.00 |
| Total expenses | 25,067.00 | 28,203.00 | 27,228.00 | 30,528.00 | 34,940.00 | 38,269.00 | 40,114.00 | 44,007.00 |
| Profit before exceptional items and tax | 5,025.00 | 5,270.00 | 7,106.00 | 9,048.00 | 9,580.00 | 11,582.00 | 14,430.00 | 16,426.00 |
| Exceptional items | -1,214.00 | -261.00 | -4,306.00 | -4,567.00 | -171.00 | -494.00 | -678.00 | -1,307.00 |
| Profit before tax | 3,810.00 | 5,010.00 | 2,799.00 | 4,481.00 | 9,408.00 | 11,088.00 | 13,752.00 | 15,119.00 |
| Current tax | 601.00 | 823.00 | 515.00 | 1,076.00 | 848.00 | 1,439.00 | 2,772.00 | 3,554.00 |
| Deferred tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax expense | 601.00 | 823.00 | 515.00 | 1,076.00 | 848.00 | 1,439.00 | 2,772.00 | 3,554.00 |
| Profit for the period | 3,208.00 | 4,172.00 | 2,272.00 | 3,389.00 | 8,513.00 | 9,610.00 | 10,965.00 | 11,509.00 |
| Profit attributable to owners | 2,665.00 | 3,765.00 | 2,904.00 | 3,273.00 | 8,474.00 | 9,576.00 | 10,929.00 | 11,479.00 |
| Profit attributable to non-controlling interests | 542.00 | 407.00 | -631.00 | 117.00 | 39.00 | 34.00 | 36.00 | 29.00 |
| Other comprehensive income | 1,680.00 | 2,121.00 | -146.00 | 557.00 | 2,257.00 | 1,142.00 | 912.00 | 3,827.00 |
| Total comprehensive income | 4,888.00 | 6,293.00 | 2,126.00 | 3,946.00 | 10,770.00 | 10,752.00 | 11,877.00 | 15,335.00 |
| Earnings per share, basic | 11.11 | 15.69 | 12.10 | 13.60 | 35.30 | 39.90 | 45.60 | 47.80 |
| Earnings per share, diluted | 11.11 | 15.69 | 12.10 | 13.60 | 35.30 | 39.90 | 45.60 | 47.80 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 74,455.00 | 80,744.00 | 79,441.00 | 85,463.00 | 88,116.00 | 92,101.00 | 103,706.00 | 108,785.00 |
| Non-current assets | 35,453.00 | 40,860.00 | 40,087.00 | 41,988.00 | 42,010.00 | 39,476.00 | 43,539.00 | 44,894.00 |
| Current assets | 39,003.00 | 39,862.00 | 39,333.00 | 43,433.00 | 46,069.00 | 52,594.00 | 60,136.00 | 63,860.00 |
| Property, plant and equipment | 10,531.00 | 10,390.00 | 10,101.00 | 10,192.00 | 10,098.00 | 10,036.00 | 10,407.00 | 11,114.00 |
| Capital work-in-progress | 806.00 | 963.00 | 1,017.00 | 1,108.00 | 1,150.00 | 1,234.00 | 1,355.00 | 1,381.00 |
| Goodwill | 7,041.00 | 8,713.00 | 8,920.00 | 8,599.00 | 8,771.00 | 8,939.00 | 9,279.00 | 9,833.00 |
| Other intangible assets | 5,397.00 | 5,317.00 | 4,753.00 | 4,420.00 | 4,164.00 | 3,611.00 | 12,123.00 | 11,875.00 |
| Inventories | 9,875.00 | 10,513.00 | 9,956.00 | 9,868.00 | 9,936.00 | 10,243.00 | 10,442.00 | 11,493.00 |
| Trade receivables | 12,201.00 | 11,439.00 | 11,303.00 | 11,249.00 | 12,942.00 | 13,046.00 | 15,396.00 | 15,510.00 |
| Cash and cash equivalents | 4,296.00 | 4,624.00 | 5,403.00 | 9,286.00 | 8,013.00 | 10,269.00 | 10,022.00 | 9,771.00 |
| Total equity and liabilities | 74,455.00 | 80,744.00 | 79,441.00 | 85,463.00 | 88,116.00 | 92,101.00 | 103,706.00 | 108,785.00 |
| Equity | 56,364.00 | 59,315.00 | 63,197.00 | 67,106.00 | 69,380.00 | 72,486.00 | 78,127.00 | 83,880.00 |
| Equity share capital | 240.00 | 240.00 | 240.00 | 240.00 | 240.00 | 240.00 | 240.00 | 240.00 |
| Other equity | 52,878.00 | 55,755.00 | 59,586.00 | 63,427.00 | 68,875.00 | 71,978.00 | 77,580.00 | 83,330.00 |
| Total liabilities | 18,091.00 | 21,428.00 | 16,244.00 | 18,357.00 | 18,736.00 | 19,615.00 | 25,580.00 | 24,905.00 |
| Non-current liabilities | 1,390.00 | 1,521.00 | 1,221.00 | 1,373.00 | 1,481.00 | 1,420.00 | 2,165.00 | 2,283.00 |
| Current liabilities | 16,701.00 | 19,906.00 | 15,023.00 | 16,984.00 | 17,255.00 | 18,194.00 | 23,415.00 | 22,622.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 3.00 | 2.00 | 31.00 |
| Borrowings, current | 3,807.00 | 6,198.00 | 1,488.00 | 2,844.00 | 2,080.00 | 1,867.00 | 4,683.00 | 4,050.00 |
| Trade payables | 5,109.00 | 5,682.00 | 5,700.00 | 5,653.00 | 5,732.00 | 6,184.00 | 6,706.00 | 7,334.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | -939.00 | 4,959.00 | 5,719.00 | 12,135.00 | 6,299.00 | 14,072.00 | 4,781.00 | 12,419.00 |
| Net cash from investing activities | -1,356.00 | -7,944.00 | 994.00 | -690.00 | -2,584.00 | -5,306.00 | -6,691.00 | -11,344.00 |
| Net cash from financing activities | 1,956.00 | 2,376.00 | -5,877.00 | -6,710.00 | -5,058.00 | -7,906.00 | 1,101.00 | -2,513.00 |
| Purchase of property, plant and equipment | 1,076.00 | 2,086.00 | 958.00 | 2,202.00 | 698.00 | 2,129.00 | 2,388.00 | 3,609.00 |
| Net increase in cash | -212.00 | 115.00 | 779.00 | 4,662.00 | -1,273.00 | 983.00 | -246.00 | -498.00 |
| con:CFO.BEFORE_TAX | -475.00 | 6,469.00 | 6,166.00 | 13,704.00 | 6,009.00 | 14,549.00 | 5,188.00 | 14,733.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 464.00 | 1,510.00 | 447.00 | 1,569.00 | -290.00 | 477.00 | 407.00 | 2,314.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 9,316.00 | 21,964.00 | 11,145.00 | 29,091.00 | 15,801.00 | 32,309.00 | 10,699.00 | 30,804.00 |
| con:INVESTMENTS_SOLD | 9,386.00 | 20,897.00 | 13,671.00 | 30,094.00 | 13,408.00 | 29,418.00 | 10,148.00 | 26,167.00 |
| con:PPE_DISPOSALS | 12.00 | 21.00 | 17.00 | 31.00 | 0.00 | 61.00 | 48.00 | 96.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 4,686.00 | 143.00 | 143.00 | 243.00 | 273.00 | 3,405.00 | 3,405.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 54.48 | 0.54 | 0.54 | 0.54 | 0.54 |
| Domestic institutions | 19.24 | 19.75 | 19.67 | 19.52 | 18.83 | 19.28 | 18.61 | 18.55 | 18.70 | 19.50 | 0.20 | 0.21 | 0.21 | 0.22 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 12.63 | 0.12 | 0.12 | 0.12 | 0.13 |
| Insurance companies | 5.12 | 5.12 | 5.06 | 5.02 | 5.06 | 4.91 | 4.94 | 4.71 | 4.85 | 5.09 | 0.06 | 0.07 | 0.07 | 0.07 |
| Foreign institutions | 16.89 | 16.48 | 16.79 | 17.07 | 17.72 | 17.23 | 18.02 | 18.05 | 17.96 | 17.26 | 0.17 | 0.16 | 0.16 | 0.15 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 | 45.52 | 0.46 | 0.46 | 0.46 | 0.46 |
| Non-institutional | 9.39 | 9.29 | 9.06 | 8.92 | 8.97 | 9.01 | 8.89 | 8.92 | 8.87 | 8.77 | 0.09 | 0.09 | 0.08 | 0.09 |
| Shares outstanding | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 | 2399334970 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Sun Pharma Laboratories Limited | Subsidiaries | Any other transaction | 111,869,830,000.00 | 19 |
| Sun Pharma Distributors Limited | Subsidiaries | Any other transaction | 69,195,320,000.00 | 11 |
| Sun Pharmaceutical Industries Inc | Subsidiaries | Any other transaction | 62,926,800,000.00 | 39 |
| Taro Pharmaceutical Industries Ltd Taro | Subsidiaries | Any other transaction | 29,886,750,000.00 | 14 |
| Libra Merger Limited | Subsidiaries | Any other transaction | 29,068,400,000.00 | 3 |
| Taro Pharmaceuticals USA Inc | Subsidiaries | Any other transaction | 13,305,250,000.00 | 23 |
| Sun Laboratories FZE | Subsidiaries | Any other transaction | 12,427,360,000.00 | 12 |
| AO Ranbaxy | Subsidiaries | Any other transaction | 3,749,730,000.00 | 11 |
| Terapia SA | Subsidiaries | Any other transaction | 3,255,840,000.00 | 14 |
| Taro Pharmaceuticals Inc | Subsidiaries | Any other transaction | 2,717,620,000.00 | 17 |
| Alkaloida Chemical Company Zrt | Subsidiaries | Any other transaction | 2,700,100,000.00 | 16 |
| Sun Pharmaceutical Industries Europe BV | Subsidiaries | Any other transaction | 2,219,810,000.00 | 34 |
| Ranbaxy Pharmaceuticals Pty Ltd | Subsidiaries | Any other transaction | 2,110,630,000.00 | 6 |
| Sun Pharma Japan Ltd | Subsidiaries | Any other transaction | 2,105,940,000.00 | 14 |
| Ranbaxy Farmaceutica Ltda | Subsidiaries | Any other transaction | 2,100,690,000.00 | 8 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-06 | Q1FY27 | Aalok Shanghvi, Dilip Shanghvi, Jayashree Satagopan, Kirti Ganorkar, Richard Ascroft | Read the call |
| 2026-05-29 | Q4FY26 | Aalok Shanghvi, Dilip Shanghvi, Jayashree Satagopan, Kirti Ganorkar, Richard Ascroft | Read the call |
| 2026-05-05 | Q4FY26 | Aalok Shanghvi, Dilip Shanghvi, Dr. Abhishek Sharma, Jayashree Satagopan, Kirti Ganorkar | Read the call |
| 2026-02-04 | Q3FY26 | Aalok Shanghvi, Dilip Shanghvi, Jayashree Satagopan, Kirti Ganorkar, Richard Ascroft | Read the call |
| 2025-11-11 | Q2FY26 | Aalok Shanghvi, Dilip Shanghvi, Jayashree Satagopan, Kirti Ganorkar, Richard Ascroft | Read the call |
| 2025-08-06 | Q1FY26 | Aalok Shanghvi, Dilip Shanghvi, Jayashree Satagopan, Kirti Ganorkar, Richard Ascroft | Read the call |
| 2025-05-29 | Q4FY25 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2025-02-06 | Q3FY25 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2024-11-04 | Q2FY25 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2024-08-07 | Q1FY25 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2024-05-29 | Q4FY24 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2024-02-06 | Q3FY24 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2023-11-08 | Q2FY24 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2023-08-09 | Q1FY24 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2023-05-31 | Q4FY23 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2023-02-01 | Q3FY23 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2022-11-05 | Q2FY23 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2022-08-03 | Q1FY23 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2022-06-02 | Q4FY22 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2022-02-03 | Q3FY22 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2021-11-11 | Q2FY22 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2021-08-06 | Q1FY22 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
| 2021-06-02 | Q4FY21 | Abhay Gandhi, C. S. Muralidharan, Dilip Shanghvi, Kirti Ganorkar | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY25 | Q3FY26 | Q4FY21 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | — | — | I don’t think we have crystallized this in specifics to be able to respond, but as I see our overall R&D spend, for us to be able to take care of bios… | — | — | — | — | — |
| Capital allocation | The Board has declared an interim dividend of INR10.50 per share for the year FY '25 against INR8.50 per share interim dividend for the previous year. | And we have also consistently indicated that we want to remain disciplined about acquisition. | The Board has proposed a final dividend of Rs. | Generally, we've kept the dividend payout at 30%+ of the profit. | While staff cost as a percentage of sales are marginally higher than last year, the increase in absolute value is on account of the annual merit incre… | So it's not a pure acquisition where we kind of buy a company and we don't know anything about it. | I think we have to wait for the acquisition to go through all the clearances. | Chief Financial Officer, Sun Pharmaceutical Industries Ltd. Dr. Abhishek Sharma VP - IR and Strategic Project, Sun Pharmaceutical Industries Ltd. Sun … |
| Costs | — | — | — | Margins have expanded despite input cost pressures and normalization of branding, promotional & travel expenses. | — | — | — | — |
| Debt and cash | — | Now, it all depends on the targets, cash flow profile, our confidence that we can repay. | So, it shouldn’t be a big drain either on our cash flow or on our probability. | Number two, is the specialty business as an SBU now breaking even on a cash flow basis? | — | So we need to find a balance and find a way by which we continue to generate growth and positive cash flow for our investors while we continue to crea… | And almost generating more than a billion-dollar free cash flow. | The net debt is having an interest charge of about 5.5%. |
| Demand | We continue to invest in building an R&D pipeline for both our generics business as well as specialty business. | Today, the Team will provide an update on financial performance and business highlights for the Quarter, Pipeline Updates and respond to any Questions… | Our R&D effort spans across both specialty and generic businesses and we continue to invest in building the pipeline for various markets including the… | We continue to invest in building a R&D pipeline for both the global generics and the specialty businesses. | And if you talk about the timeframe we could also have other interesting products in the pipeline. | We continue to invest in building an R&D pipeline for both the Global generics and the Specialty businesses. | But this includes whatever that we have in the pipeline. | As we just went through the presentation and looked at the deal rationale, there are several opportunities that present before us which has the potent… |
| Guidance | Because of delay in our clinical spends, our R&D expenditure is trending below our guidance and for the full year. | We should increase in the R&D spend and next quarter we will guide R&D next year. | And lastly on the guidance for FY22. Given the uncertainties of the pandemic in the near term, we are refraining from giving a guidance for FY22. Howe… | we expect the clinical trials to pick up in this year, so that we can complete or we can progress with the clinical studies rapidly. | No, I think our current guidance is that we should be filing the product by second quarter, which I think because of the FDA hold on 12 milligram, we … | But otherwise, the overall guidance is a consolidated guidance for all businesses. | Which is what I said is that we don't actually look at this as a cost we look at this as an investment and we expect this to further help us strengthe… | On the guidance, we expect high single-digit consolidated top line growth for FY27 based on our current understanding of the regulatory and macro envi… |
| Margin | EBITDA, including other operating revenues, was Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 | Having said that better mix of products both in terms of the branded products and our innovative medicines has given an uptick compared to the gross m… | For Sun Pharma, the sales in the second half were higher by 8% compared to H1, EBITDA was up by almost 13% and adjusted net profit was up by approxima… | 237 million in FY21. EBITDA for the full year was at Rs. | EBITDA for Q4 was Rs.28,021 million, including other operating revenues up by 19.7% over Q4 last year with EBITDA margins at 25.6%. | So while you are right that we have seen an upward movement of gross margin in Q4, however, it's difficult to say at this juncture what we feel is tha… | 564 million in Q4 FY24. EBITDA including other operating revenues was at Rs. | There is a certain amount of debt that we're taking, it's within the safety margin of what people consider to be safe and with an intention to repay t… |
| People | — | — | — | — | — | Staff cost stands at 19.7% of sales, higher versus last year on account of annual merit increase, consolidation of Concert and increased headcount in … | Mainly due to this year, we have also said that utilization of the past losses we exhausted. | Do you have any sense of the level of attrition that Organon is facing currently and is that something you need to address to stabilize the business? |
| Pricing | But our focus is on growing the specialty business in Japan because the generic business has become very challenging in terms of pricing and overall a… | The first one is on the CMS's proposal on the most favored nation pricing, the two models that they have put out. | — | No. I think hopefully; we should be able to offset some of the cost increases with our ability to take a price increase in the marketplace. | So, the price increase that we take for the specialty products at least in the US, I can't answer this question on a global basis is very nominal. | So Abhay, maybe you can respond about the pricing. | On pricing, I think we have consistently said that it's product-specific thing, and nothing which I can speak to on a generalized basis. | On established product portfolio in China, has the impact of volume-based pricing already kind of in the numbers and… |
| Revenue growth | Besides the underlying business growth, we also had milestone income in ROW in Q3. Ex-milestones, overall sales growth was 8.9%. | As usual, we will look at Key Consolidated Financials of the Company: During the 3rd Quarter of FY 2026, we recorded sales of Rs.1,54,691 million, reg… | 26,709 million, recording a growth of 12.9% over Q4 last year. | I am happy to report that our topline for FY22 has crossed the US$ 5 billion mark while the net profit has crossed US$ 1 billion. | The full year FY23 sales were at Rs.432,789 million, a growth of 12.6% over the same period last year. | The full year FY '24 sales were at INR477,585 million, a growth of 10.4% over last year. | 520,412 million a growth of 9% over last year. | Two different companies with similar top line and actually their EBITDA is higher than Sun, one valued at close to $10 billion, the other in excess of… |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-11-05 | Q2FY23 | Dilip Shanghvi | So, I think our guidance is 6% to 8%. |
| 2023-02-01 | Q3FY23 | Dilip Shanghvi | We shared at the time of sharing the information about Halol, is that based on this, we expect the impact to be less than 3% of the total sales. |
| 2025-08-06 | Q1FY26 | Jayashree Satagopan | And we expect for the full year to be around 25%. |
| 2025-11-11 | Q2FY26 | Jayashree Satagopan | Our ETR has gone up to 24.5% and we expect it to be hovering around 25%. |
| 2026-05-29 | Q4FY26 | Dilip Shanghvi | We expect our FY27 R&D spend to be 6% to 7% of the sales for the next year. |
| 2026-05-29 | Q4FY26 | Jayashree Satagopan | We expect the effective tax rate to be in the range of 25%. |